RNA startup ADARx raises $200M from Bain, TCGX to bring RNAi 'to the next level'
The RNA startup ADARx Pharmaceuticals has raised a $200 million Series C, aiming to advance multiple clinical programs that directly challenge the leaders of the RNA interference space.
The San Diego biotech announced the round, led by Bain Capital Life Sciences and TCGX, on Wednesday and plans to grow from 50 to 80 employees over the next year. ADARx emerged from stealth in the fall of 2021 alongside a $75 million Series B round.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
